Medical Oncology

, Volume 29, Issue 2, pp 595–599

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer

  • Jing Deng
  • Wei Jia Fang
  • Xiao Chen Zhang
  • Dong Ping Wu
  • Hong Ming Fang
  • Jing Chen
  • Jiong Qian
  • Hai Bo Mou
  • Bin Bin Chu
  • Nong Xu
  • Li Song Teng
Original Paper

DOI: 10.1007/s12032-011-9891-2

Cite this article as:
Deng, J., Fang, W.J., Zhang, X.C. et al. Med Oncol (2012) 29: 595. doi:10.1007/s12032-011-9891-2

Abstract

A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Of the 40 evaluable female patients, the ORR was 62.5%. All patients have responded with one (2.5%) complete response, 24 (60%) partial response, 12 (30%) stable disease, and 3 (7.5%) progressive disease. The OS and PFS were 20 months (95% CI: 11.9–28 months) and 13 months (95% CI: 8.0–17.9 months), respectively. Survival (OS and PFS) were longer in patients with good performance status and in patients older than 65 years (P < 0.05). The most frequently observed toxicities were rash/dry skin (80%), diarrhea (42.5%), and vomiting/anorexia (32.5%). Four patients developed grade 3 toxicities (rash and diarrhea) but did not require either dose reduction or discontinuation. Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC.

Keywords

Gefitinib Female Pretreated Non-small-cell lung cancer 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jing Deng
    • 1
  • Wei Jia Fang
    • 1
  • Xiao Chen Zhang
    • 1
  • Dong Ping Wu
    • 3
  • Hong Ming Fang
    • 4
  • Jing Chen
    • 1
  • Jiong Qian
    • 1
  • Hai Bo Mou
    • 1
  • Bin Bin Chu
    • 5
  • Nong Xu
    • 1
  • Li Song Teng
    • 2
  1. 1.Department of Medical OncologyThe First Hospital Affiliated to Medical School of Zhejiang UniversityHangzhouChina
  2. 2.Department of Oncological SurgeryThe First Hospital Affiliated to Medical School of Zhejiang UniversityHangzhouChina
  3. 3.Department of RadiotherapyShaoxing People’s HospitalShaoxingChina
  4. 4.Department of Medical OncologyXiaoshan HospitalHangzhouChina
  5. 5.Department of Medical OncologyMingzhou HospitalNingboChina

Personalised recommendations